HB Therapeutics, Inc. is a start-up biotech specialized in discovery and development of small-molecule degraders of oncogenic and aging proteins as the next generation of anticancer and antiaging drugs. The company has developed novel cell-based platforms of targeted protein degradation for discovery of small-molecules that selectively initiate ubiquitination and degradation of targeted proteins.
The company is located in the Indiana Center for Biomedical Innovation, Indianapolis. The first small-molecule degraders of small ubiquitin-like modifier-1 (SUMO1) are now under preclinical development as the first-in-class anticancer drugs. The small molecule degraders of other oncoproteins and aging amyloid precursor protein are in pipeline for new drug development.